OncoMatch/Clinical Trials/NCT05277844
Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC
Is NCT05277844 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies TKI for oligometastatic disease.
Treatment: TKI — A Phase II randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic Non-small cell lung cancer patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: EGFR driver mutation
Patients with positive oncogene driver mutation (EGFR or ALK/ROS)
Required: ALK driver mutation
Patients with positive oncogene driver mutation (EGFR or ALK/ROS)
Required: ROS1 driver mutation
Patients with positive oncogene driver mutation (EGFR or ALK/ROS)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: tyrosine kinase inhibitor
Patients who have received at least 2-4 months of TKI therapy without progression
Cannot have received: radiation therapy
Patients with prior history of radiation therapy to thorax
Lab requirements
Blood counts
ANC ≥ 500 cells/mm3; Platelets ≥ 50,000 cells/mm3; Hemoglobin ≥ 8.0 g/dl (Use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable)
Adequate end-organ function CBC/differential obtained within 15 days prior to registration on study, with adequate bone marrow function defined as follows: Absolute neutrophil count (ANC) ≥ 500 cells/mm3; Platelets ≥ 50,000 cells/mm3; Hemoglobin ≥ 8.0 g/dl (Use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dl is acceptable);
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify